GlassScriptPhysician profile
Mohammad H. Wadud
NPI 1831622141
$5,482.29
in general payments reported to CMS, 2019-2025
33 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.92 · 2020: $83.60 · 2021: $361 · 2022: $801 · 2023: $1,297 · 2024: $1,406 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,219.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,268.10 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $660.55 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $491.11 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.26 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Exact Sciences Corporation | $261.17 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $256.22 | 2023-2025 | Voquezna |
| Glaxosmithkline, LLC. | $253.21 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $212.30 | 2021-2024 | |
| Abbvie INC. | $194.41 | 2022-2025 | Viberzi, Linzess, Creon |
| Novartis Pharmaceuticals Corporation | $181.54 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.00 | 2021-2024 | Xifaxan |
| Amgen INC. | $167.64 | 2022-2025 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $159.69 | 2022-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $89.19 | 2023-2024 | |
| Shield Therapeutics INC | $86.99 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $86.46 | 2024-2025 | Veozah |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.63 | 2020 | |
| Merck Sharp & Dohme LLC | $70.00 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $63.29 | 2021-2023 | Heplisav-B |
| Heartflow, INC. | $59.29 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $46.98 | 2021-2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $39.99 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $35.62 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $30.47 | 2024-2025 | Trintellix |
| Phadia US INC. | $30.47 | 2022 | |
| Neurocrine Biosciences, INC. | $26.80 | 2025 | |
| Corcept Therapeutics | $23.17 | 2025 | Korlym |
| Almatica Pharma LLC | $21.41 | 2025 | Loreev Xr |
| Radius Health, INC. | $20.53 | 2025 | Tymlos |
| Philips North America LLC | $20.01 | 2023 | |
| Abbott Laboratories | $17.00 | 2021 | |
| Amarin Pharma, INC. | $15.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.53 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Wadud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.